Aliases:This biomarker is also known as:
- Cholecystokinin-Releasing Peptide, Trypsin-Sensitive,
- Diazepam-Binding Inhibitor,
- Acyl-CoA-Binding Protein,
- GABA Receptor Modulator,
- diazepam binding inhibitor (GABA receptor modulator, acyl-CoA binding protein),
- Acyl-Coenzyme A Binding Domain Containing 1,
DBI, diazepam binding inhibitor, was previously known as ACBP, acyl-coA binding protein. This protein is regulated by hormones, is involved in lipid metabolism, and is thought to act as a neuropeptide to regulate the action of the GABA receptor. DBI is conserved across species. The most highly conserved domain is the hydrophobic binding site for medium- and long-chain acyl-coA esters. DBI is involved in the regulation of pancreatic secretion and release of cholecystokinin. There are three pseudogenes for DBI on separate chromosomes. DBI has multiple transcript variants encoding different isoforms.
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
|QA State:||Under Review|
The role of ACBP, also known as DBI, in lung tumorigenesis is unknown. ACBP plays a role in lipid metabolism and acts as acyl-CoA transporter and intracellular pool former. In spite of the fact that ACBP is ubiquitously expressed (29), its differential expression in normal epithelium and invasive tissues was clearly demonstrated by MALDI MS. To our knowledge, this is the first report of overexpression of ACBP in lung tumorigenesis.
ACBP, also known as DBI, belongs to a 9-member panel that provides a quantitative measure of the probability of having lung cancer that goes beyond the histological evaluation of preinvasive lesions. The identified members of the panel are TMSB4X (Thymosin beta-4), Ubiquitin, des-ubiquitin, ACBP, CSTA, Cytochrome C, and MIF.